Clinical Trials Logo

Cerebral Infarction clinical trials

View clinical trials related to Cerebral Infarction.

Filter by:

NCT ID: NCT06240468 Recruiting - Clinical trials for Acute Ischemic Stroke

Dynamic Changes in Human Microbiome Predict the Risk of Adverse Outcomes in Patients With Acute Ischemic Stroke: a Multicenter Prospective Cohort Study

Start date: February 10, 2022
Phase:
Study type: Observational

(1) The main purpose To explore the predictive value of human microbiome and its metabolome for adverse prognosis in patients with acute ischemic stroke (AIS). (2) Secondary purposes 1. To explore the characteristics of cross-regional disturbance of human microbiome in stroke patients; 2. To investigate the characteristics and rules of bacterial flora changes before and after recurrent apoplexy; 3. Markers closely related to AIS prognosis and cognitive emotional complications were excavated by metagenomic, metabolic, peptide and imaging groups. 4. To explore the relationship between serum markers of ultra early stage and prognosis.

NCT ID: NCT06238024 Recruiting - Ischemic Stroke Clinical Trials

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

IRIS
Start date: February 2, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment

NCT ID: NCT06221371 Recruiting - Clinical trials for Ischemic Stroke, Acute

Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion

TNK-PLUS
Start date: December 16, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of endovascular treatment with or without preceding intravenous Tenecteplase in patients with late-window (4.5-24 hours of symptom onset) acute ischemic stroke due to middle cerebral artery (MCA) M1 or M2 occlusion.

NCT ID: NCT06210646 Recruiting - Ischemic Stroke Clinical Trials

Citicoline in Ischemic Stroke, a Randomized Trial

Start date: December 29, 2023
Phase: Phase 3
Study type: Interventional

Along with the current clinical trial, the efficacy and safety of a 1000 mg daily citicoline administered within 24 hours of the first-ever ischemic stroke and lasted 12 months compared to placebo were assessed through MoCA, NIHSS, mRS, and possible adverse effects.

NCT ID: NCT06202755 Recruiting - Ischemic Stroke Clinical Trials

Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke

Start date: December 12, 2022
Phase: Phase 3
Study type: Interventional

Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through NIHSS, mRS, and possible adverse effects.

NCT ID: NCT06202378 Recruiting - Clinical trials for Acute Ischemic Stroke

Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke

Start date: December 28, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to determine the safety and efficacy of SHPL-49 intravenous infusion for 7 consecutive days in the treatment of acute ischemic stroke subjects.

NCT ID: NCT06200753 Recruiting - Clinical trials for Acute Ischemic Stroke

Triage of Patients Presenting Beyond 24 Hours With Acute Ischemic Stroke Due to Large Vessel Occlusions (TRACK-LVO Late)

TRACK-LVO Late
Start date: January 1, 2018
Phase:
Study type: Observational

The objective of this study is to create a comprehensive, multi-center, TRACK-LVO registry-linked cohort of consecutive patients with acute ischemic stroke (AIS) caused by large vessel occlusions (LVO) and presenting to each participating center beyond 24 hours from last known well, who are treated with either endovascular therapy (EVT) or the best available medical management (BMM).

NCT ID: NCT06196047 Recruiting - Ischemic Stroke Clinical Trials

Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA

Start date: December 1, 2021
Phase: Phase 3
Study type: Interventional

Along with the current clinical trial, the efficacy and safety of ticagrelor and aspirin administered within the first 24 hours of first-ever ischemic stroke compared to cilostazol and aspirin were assessed through NIHSS, mRS, and possible adverse effects.

NCT ID: NCT06194968 Recruiting - Clinical trials for Acute Ischemic Stroke

Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study

Start date: December 30, 2023
Phase:
Study type: Observational

The purpose of this study is to to compare the safety and effectiveness of IV urokinase with IV alteplase in the treatment of AIS in patients up to 6 hours from symptom onset.

NCT ID: NCT06157502 Recruiting - Clinical trials for Ischemic Stroke, Acute

Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

Start date: January 11, 2024
Phase: Phase 3
Study type: Interventional

Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.